CIM
NKGN

Corbyn Investment Management’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Corbyn Investment Management’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,320
Closed -$113K – 67
2022
Q4 		$113K Hold
11,320
– – 0.04% 64
2022
Q3 		$110K Hold
11,320
– – 0.05% 70
2022
Q2 		$110K Hold
11,320
– – 0.04% 76
2022
Q1 		$110K Buy
+11,320
New +$110K 0.04% 86

Other funds holding NKGN

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Corbyn Investment Management's NKGN Position: Q1 2023 in Review

Corbyn Investment Management sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2023, closing a stake of 11,320 shares — an estimated $113K sold.

Corbyn Investment Management first reported a position in NKGN in Q1 2022 and held it in 4 quarters. The position peaked at $113K in Q4 2022. 55 funds tracked by Wall St. Rank hold NKGN as of Q1 2023.

  • Corbyn Investment Management reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Corbyn Investment Management sold 11,320 NKGen Biotech, Inc. Common Stock shares in Q1 2023, an estimated $113K.
  • Corbyn Investment Management first reported a position in NKGen Biotech, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
  • Corbyn Investment Management's NKGen Biotech, Inc. Common Stock position peaked at $113K in Q4 2022.
  • 55 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2023.

Based on Corbyn Investment Management's 13F filing for Q1 2023, filed 2 May 2023.